Precigen News

Canto Fitzgerald: Reiterates Precigen's (PGEN.US) holdings increase rating.

Canto Fitzgerald: Reiterates Precigen's (PGEN.US) holdings increase rating.

Zhitong FinanceMay 15 20:40

Cantor Fitzgerald Reiterates Overweight on Precigen

Cantor Fitzgerald analyst Jennifer Kim reiterates Precigen (NASDAQ:PGEN) with a Overweight.

BenzingaMay 15 20:39

Precigen Is Maintained at Buy by Stifel

Precigen Is Maintained at Buy by Stifel

Dow JonesMay 15 20:03

HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $6 price target.

BenzingaMay 15 18:41

Precigen | 10-Q: Quarterly report

SEC announcementMay 15 05:25 · Announcements

Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, Vs. Street Est of $1.5M

04:15 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M

MT NewswiresMay 15 04:15

Precigen Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $1.06M Miss $1.48M Estimate

Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is unchanged from the same period last year. The co

BenzingaMay 15 04:14

Precigen 1Q Rev $1.07M >PGEN

Precigen 1Q Rev $1.07M >PGEN

Dow JonesMay 15 04:05

Press Release: Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Dow JonesMay 15 04:05 · Earnings

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd Following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

GERMANTOWN, Md., May 8, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p

PR NewswireMay 9 04:05

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)

TipRanksMay 8 13:10

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients With Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

PR NewswireApr 24 22:20

AnaptysBio Names Thomas Smart as CEO >ANAB

AnaptysBio Names Thomas Smart as CEO >ANAB

Dow JonesApr 24 21:01

Press Release: Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to t

Dow JonesApr 24 21:00

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HP

PR NewswireMar 29 04:05

Precigen Shares Fall After Downgrade From JPMorgan

Precigen (PGEN) shares were down 9% in regular Friday trading after JPMorgan downgraded the company to underweight from neutral. Trading volume was nearly 1.5 million shares against a daily average of

MT NewswiresMar 23 04:14

Precigen Cut to Underweight From Neutral by JP Morgan

Precigen Cut to Underweight From Neutral by JP Morgan

Dow JonesMar 23 00:22

J.P. Morgan Cuts Precigen to Underweight, Cites Burn Rate

Seeking AlphaMar 22 23:10

Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 20 22:07

Precigen Price Target Maintained With a $14.00/Share by JMP Securities

Precigen Price Target Maintained With a $14.00/Share by JMP Securities

Dow JonesMar 20 21:51